Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: J Cardiovasc Pharmacol. 2008 Oct;52(4):355–362. doi: 10.1097/FJC.0b013e3181893659

Figure 2.

Figure 2

LV peak +dP/dt and LV wall thickening were computed as relative changes from baseline values in both the wild type (WT) and the tumor necrosis factor-α receptor I knockout (TNFRInull) mice following I/R, with or without aprotinin (APRO) administration. LV peak +dP/dt fell in all groups following I/R with the exception of the TNFRInull group receiving vehicle only. LV wall thickening in the TNFRInull with APRO group was significantly reduced as compared to baseline, while the other groups did not change significantly. (* = p<0.05 vs Baseline)